Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy
dc.contributor.author | Yoshizawa, Hirohisa | en_US |
dc.contributor.author | Sakai, Keisuke | en_US |
dc.contributor.author | Chang, Alfred E. | en_US |
dc.contributor.author | Shu, Suyu | en_US |
dc.date.accessioned | 2006-04-10T14:44:48Z | |
dc.date.available | 2006-04-10T14:44:48Z | |
dc.date.issued | 1991-05 | en_US |
dc.identifier.citation | Yoshizawa, Hirohisa, Sakai, Keisuke, Chang, Alfred E., Shu, Suyu (1991/05)."Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy." Cellular Immunology 134(2): 473-479. <http://hdl.handle.net/2027.42/29366> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6WCF-4DKVCTY-R0/2/db0585b3d22c37f1251e1e475a5c0abe | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/29366 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=1827049&dopt=citation | en_US |
dc.description.abstract | Lymph nodes draining progressive tumors contain tumor-sensitized but not functional preeffector T lymphocytes. These cells can acquire antitumor reactivity after stimulation with tumor cells and interleukin-2 (IL-2). We demonstrated here that, in the absence of tumor cells, preeffector cells could be stimulated and expanded by sequential culture with anti-CD3 monoclonal antibody and IL-2. The adoptive transfer of such activated cells mediated immunologically specific reductions of established pulmonary metastases. The therapeutic effects could be enhanced by the administration of IL-2. This activation represents a secondary immune response because effector cells could be generated only from tumor-draining but not from normal or adjuvant-stimulated lymph nodes. Furthermore, treatment of advanced metastases with these cells resulted in prolongation of survival and cure of the disease. Thus, anti-CD3 may serve as a universal reagent for activating tumor-sensitized T lymphocytes for cancer therapy. | en_US |
dc.format.extent | 136142 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Surgery, University of Michigan, Ann Arbor, Michigan 48109, USA | en_US |
dc.contributor.affiliationum | Department of Surgery, University of Michigan, Ann Arbor, Michigan 48109, USA | en_US |
dc.contributor.affiliationum | Department of Surgery, University of Michigan, Ann Arbor, Michigan 48109, USA | en_US |
dc.contributor.affiliationum | Department of Surgery, University of Michigan, Ann Arbor, Michigan 48109, USA | en_US |
dc.identifier.pmid | 1827049 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/29366/1/0000436.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0008-8749(91)90318-6 | en_US |
dc.identifier.source | Cellular Immunology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.